Immutep Ltd Cash Flow Conversion Efficiency
Immutep Ltd cash flow conversion efficiency. Based on the latest financial reports, Immutep Ltd (IMM) has a cash flow conversion efficiency ratio of -0.233x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (AU$-33.50 Million ≈ $-23.71 Million USD) by net assets (AU$143.64 Million ≈ $101.63 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Immutep Ltd (2004–2025)
Cash flow conversion efficiency of Immutep Ltd from 2004 to 2025. This chart illustrates how Immutep Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. View today's stock price for Immutep Ltd for real-time trading data and today's change.
Immutep Ltd Cash Flow Conversion Ratio Explained
Immutep Ltd cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Immutep Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Immutep Ltd ranked by their cash flow conversion efficiency. Also see IMM company net worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Maniker F & G Co. Ltd
KQ:195500
|
0.043x |
|
Daebo Magnetic Co.Ltd
KQ:290670
|
-0.063x |
|
Formetal Co. Ltd
KQ:119500
|
-0.013x |
|
OPCOM Holdings Bhd
KLSE:0035
|
-0.001x |
|
Aciselsan Acipayam Seluloz Sanayi Ve Ticaret AS
IS:ACSEL
|
0.026x |
|
Kidoz Inc
V:KIDZ
|
0.061x |
|
SP Systems Co.Ltd
KQ:317830
|
0.010x |
|
Protasco Bhd
KLSE:5070
|
0.007x |
Annual Cash Flow Conversion Efficiency for Immutep Ltd (2004–2025)
The table below shows the annual cash flow conversion efficiency of Immutep Ltd from 2004 to 2025. Review Immutep Ltd free cash flow generation to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-06-30 | AU$143.64 Million ≈ $101.63 Million |
AU$-62.05 Million ≈ $-43.90 Million |
-0.432x | -135.12% |
| 2024-06-30 | AU$189.52 Million ≈ $134.10 Million |
AU$-34.82 Million ≈ $-24.64 Million |
-0.184x | +30.12% |
| 2023-06-30 | AU$136.47 Million ≈ $96.56 Million |
AU$-35.88 Million ≈ $-25.39 Million |
-0.263x | +18.17% |
| 2022-06-30 | AU$94.08 Million ≈ $66.57 Million |
AU$-30.23 Million ≈ $-21.39 Million |
-0.321x | -33.47% |
| 2021-06-30 | AU$73.27 Million ≈ $51.84 Million |
AU$-17.64 Million ≈ $-12.48 Million |
-0.241x | +26.04% |
| 2020-06-30 | AU$33.30 Million ≈ $23.56 Million |
AU$-10.84 Million ≈ $-7.67 Million |
-0.326x | +48.07% |
| 2019-06-30 | AU$24.39 Million ≈ $17.26 Million |
AU$-15.29 Million ≈ $-10.82 Million |
-0.627x | -176573.57% |
| 2018-06-30 | AU$33.52 Million ≈ $23.72 Million |
AU$-11.89K ≈ $-8.42K |
0.000x | +99.89% |
| 2017-06-30 | AU$26.53 Million ≈ $18.77 Million |
AU$-8.51 Million ≈ $-6.02 Million |
-0.321x | -0.12% |
| 2016-06-30 | AU$35.32 Million ≈ $24.99 Million |
AU$-11.31 Million ≈ $-8.00 Million |
-0.320x | -1.53% |
| 2015-06-30 | AU$24.69 Million ≈ $17.47 Million |
AU$-7.79 Million ≈ $-5.51 Million |
-0.315x | +49.92% |
| 2014-06-30 | AU$22.59 Million ≈ $15.99 Million |
AU$-14.23 Million ≈ $-10.07 Million |
-0.630x | -14.85% |
| 2013-06-30 | AU$29.25 Million ≈ $20.70 Million |
AU$-16.04 Million ≈ $-11.35 Million |
-0.548x | -6.56% |
| 2012-06-30 | AU$37.16 Million ≈ $26.29 Million |
AU$-19.12 Million ≈ $-13.53 Million |
-0.515x | -190.62% |
| 2011-06-30 | AU$55.10 Million ≈ $38.99 Million |
AU$-9.76 Million ≈ $-6.90 Million |
-0.177x | +54.00% |
| 2010-06-30 | AU$16.79 Million ≈ $11.88 Million |
AU$-6.46 Million ≈ $-4.57 Million |
-0.385x | +62.96% |
| 2009-06-30 | AU$1.81 Million ≈ $1.28 Million |
AU$-1.88 Million ≈ $-1.33 Million |
-1.039x | -76.06% |
| 2008-06-30 | AU$2.63 Million ≈ $1.86 Million |
AU$-1.55 Million ≈ $-1.10 Million |
-0.590x | +27.67% |
| 2007-06-30 | AU$4.08 Million ≈ $2.89 Million |
AU$-3.33 Million ≈ $-2.36 Million |
-0.816x | -2.03% |
| 2006-06-30 | AU$6.32 Million ≈ $4.47 Million |
AU$-5.05 Million ≈ $-3.57 Million |
-0.800x | -40.92% |
| 2005-06-30 | AU$8.34 Million ≈ $5.90 Million |
AU$-4.73 Million ≈ $-3.35 Million |
-0.568x | +48.43% |
| 2004-06-30 | AU$5.13 Million ≈ $3.63 Million |
AU$-5.64 Million ≈ $-3.99 Million |
-1.100x | -- |
About Immutep Ltd
Immutep Limited, a biotechnology company, engages in developing novel Lymphocyte Activation Gene-3 related immunotherapies for cancer and autoimmune diseases in Australia. Its lead product candidate is the eftilagimod alfa (efti or IMP321), a soluble LAG-3lg fusion based on LAG-3 immune control mechanism for the treatment of different types of cancers. The company's product pipeline also includes… Read more